Physician profile
Peter M Rosenberg
NPI 1104890664
$12,423.98
in general payments reported to CMS, 2019-2025
35 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $783 · 2021: $1,799 · 2022: $2,409 · 2023: $1,454 · 2024: $2,203 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,424.36 |
| Education | $277.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,739.77 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,344.81 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.73 | 2019-2025 | Xifaxan |
| Pfizer INC. | $717.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $604.95 | 2019-2024 | Entyvio |
| Lilly USA, LLC | $366.33 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $313.21 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $269.62 | 2019-2024 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $242.54 | 2019-2022 | |
| Novo Nordisk INC | $183.66 | 2025 | Wegovy |
| Qol Medical, LLC | $176.65 | 2021-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $170.11 | 2024 | Zymfentra, Vegzelma |
| Gilead Sciences, INC. | $169.19 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $163.13 | 2019-2024 | |
| Boston Scientific Corporation | $137.03 | 2025 | General - Therapies |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $133.19 | 2023-2025 | Capsocam Plus |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Madrigal Pharmaceuticals | $108.52 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $99.82 | 2024-2025 | Vowst |
| Endogastric Solutions, INC | $80.40 | 2019 | |
| Phathom Pharmaceuticals, INC. | $75.73 | 2023-2024 | Voquezna |
| Erbe USA INC | $74.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.27 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $54.23 | 2019-2020 | |
| Covidien Lp | $50.85 | 2019 | |
| Genzyme Corporation | $38.87 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $37.23 | 2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2024 | Cyltezo |
| Exact Sciences Corporation | $23.21 | 2023 | Cologuard Collection Kit |
| Sandoz INC. | $21.94 | 2024 | Hyrimoz |
| Phadia US INC. | $18.03 | 2019 | |
| Lucid Diagnostics INC. | $16.75 | 2022 | |
| Celgene Corporation | $16.41 | 2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $15.32 | 2023 | |
| Evoke Pharma, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.